Uptake Index of $^{123}$I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease

Yoshito Kamiya$^{1,2}$, Satoru Ota$^1$, Shintaro Okumiya$^1$, Kosuke Yamashita$^3$, Akihiro Takaki$^4$, Shigeki Ito$^4*$

$^1$ Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
$^2$ Fujifilm RI Pharma Co., Ltd., Tokyo, Japan
$^3$ Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
$^4$ Department of Medical Imaging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

**Abstract**

**Objective(s):** Iodine-123 metaiodobenzylguanidine ($^{123}$I-MIBG) myocardial scintigraphy has been used to evaluate cardiac sympathetic denervation in Lewy body disease (LBD), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The heart-to-mediastinum ratio (H/M) in PD and DLB is significantly lower than that in Parkinson's plus syndromes and Alzheimer's disease. Although this ratio is useful for distinguishing LBD from non-LBD, it fluctuates depending on the system performance of the gamma cameras. Therefore, a new, simple quantification method using $^{123}$I-MIBG uptake analysis is required for clinical study. The purpose of this study was to develop a new uptake index with a simple protocol to determine $^{123}$I-MIBG uptake on planar images.

**Methods:** The $^{123}$I-MIBG input function was obtained from the input counts of the pulmonary artery (PA), which were assessed by analyzing the PA time-activity curves. The heart region of interest used for determining the H/M was used for calculating the uptake index, which was obtained by dividing the heart count by the input count.

**Results:** Forty-eight patients underwent $^{123}$I-MIBG chest angiography and planar imaging, after clinical feature assessment and tracer injection. The H/M and $^{123}$I-MIBG uptake index were calculated and correlated with clinical features. Values for LBD were significantly lower than those for non-LBD in all analyses (P<0.001). The overlapping ranges between non-LBD and LBD were 2.15 to 2.49 in the H/M method, and 1.04 to 1.22% in the uptake index method. The diagnostic accuracy of the uptake index (area under the curve (AUC), 0.98; sensitivity, 96%; specificity, 91%; positive predictive value (PPV), 90%; negative predictive value (NPV), 93%; and accuracy, 92%) was approximately equal to that of the H/M (AUC, 0.95; sensitivity, 93%; specificity, 91%; PPV, 90%; NPV, 93%; and accuracy, 92%) for discriminating patients with LBD and non-LBD.

**Conclusion:** A simple uptake index method was developed using $^{123}$I-MIBG planar imaging and the input counts determined by analyzing chest radiisotope angiography images of the PA. The diagnostic accuracy of the uptake index was approximately equal to that of the H/M for discriminating patients with LBD and non-LBD.

**Keywords:** Iodine-123, metaiodobenzylguanidine, Lewy body disease, Quantification, Uptake index
disease (LBD), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB) (5, 6).

The heart-to-mediastinum ratio (H/M), determined using planar images, has been used for quantifying cardiac $^{123}$I-MIBG uptake (2, 7). The H/M in LBD is significantly lower than that in Parkinson's plus syndromes and LBD from Alzheimer's disease (AD) (5, 8). However, this method has limited accuracy because the H/M is obtained from two-dimensional image analysis, and is significantly affected by scatter from nearby organs and image acquisition parameters. Furthermore, the H/M fluctuates according to system performance (mainly collimator performance: low-energy, medium energy, low-medium energy, etc.) of the gamma cameras (9, 10). As a countermeasure, Nakajima et al. described the results of a large Japanese multicenter initiative (84 institutions), reporting cross-institution phantom calibrations for the measurement of the planar H/M by using standard nuclear cameras and collimators from a variety of vendors in order to obtain a standardized H/M (11, 12).

However, collimators with the same designation from different vendors have very different characteristics (13). Additionally, a complex experiment using a special phantom is required for calibrating system performance. Therefore, a new, simple method is required for quantifying cardiac $^{123}$I-MIBG uptake. Chen et al. and van der Veen et al. proposed that more accurate and reliable H/Ms may be obtained using single photon emission tomography (SPECT) imaging (14, 15). The results generated for the H/M are a relative uptake measure, and thus depend on the system performance of the gamma cameras. Previously, a quantification method using a retention index of the tracer in positron-emission tomography (PET) has been proposed (16, 17). The retention index was calculated using the ratio of arterial-blood counts and myocardial counts obtained using $^{123}$I-MIBG cadmium zinc telluride (CZT) SPECT image analysis (18). A simple and noninvasive image analysis technique without arterial blood sampling will also be useful in the clinical setting. Therefore, a simple, noninvasive quantification method using $^{123}$I-MIBG uptake image analysis is required for routine clinical study.

We recently developed an 1-123-N-isopropyl-p-iodoamphetamine ($^{123}$I-IMP) microsphere method for quantifying cerebral blood flow by using chest dynamic planar images and brain SPECT (19). In addition, we developed a fully automated input function program by using the area under the curve (AUC) of the pulmonary artery (PA) and the integrated lung washout ratio (20). The AUC determination method for the PA could be applied for determining the input counts of $^{123}$I-MIBG (20). The output counts, as determined using the $^{123}$I-MIBG heart counts, could be analyzed using planar images.

The purpose of this study was to develop a new noninvasive quantification method with a simple protocol to determine $^{123}$I-MIBG uptake on planar images.

**Methods**

**Theory**

The input count obtained using the integrated counts of the time-activity curve (TAC) on the PA region of interest (ROI) of the chest radioisotope (RI) angiography images is directly proportional to the administration dose (20). Therefore, the uptake index can be noninvasively calculated as follows:

\[
\text{Uptake index} = \left( \frac{\text{output count}}{\text{input count}} \right) \times 100 \%
\]  

where output count (counts/pixel) is the heart count on the planar image.

The heart count (counts/pixel) was obtained by subtracting the background (BG) count (counts/pixel). The BG count was obtained by setting the ROI on the axillary dissection of the planar image.

Figure 1 shows the scheme used for determining the uptake index. The first peak of the TAC was fitted with a gamma function, and the AUC was obtained by integrating the gamma functions. The heart ROI used for the H/M method was used for calculating the uptake index (Figure 1).

**Subjects**

Table 1 lists the diseases of the patients who visited Chibana Clinic. Images collected from 48 patients (21 men, 27 women; age range: 56-89 years; mean age: 73.5 years) with clinically suspected LBD who underwent both $^{123}$I-MIBG chest RI angiography and planar imaging at the clinic between December 2013 and April 2014 were used for developing the theory and procedure for this new quantification method (Table 1). Clinical diagnosis was performed by a neurologist according to the neurological testing criteria for PD (21), DLB (22), and AD (23). Magnetic resonance imaging was used to rule out related diseases. None of the patients had cardiac disease, diabetes, and pulmonary disease. The age and sex were not significantly different between the patients in the two groups.

The study was approved by the Ethics Committee of Medicine at Chibana Clinic and the Kumamoto University for Human Studies, and written informed consent was obtained from all patients before the study began. All imaging data were handled anonymously, in accordance with the
guidelines of the Declaration of Helsinki and the regulation of each institution’s ethics board.

**Study protocol**

**Chest RI angiography**

To determine the input function, \(^{123}\text{I}\)-MIBG chest RI angiography images in the anterior view were obtained for 2 min (1 s/frame, 128×128 matrix, and 3.3 mm/pixel) by using a detector equipped with low-medium-energy, general-purpose collimators after a bolus injection of 111 MBq of \(^{123}\text{I}\)-MIBG. The TAC of the PA was obtained by placing a circular ROI with a diameter of 3 pixels on the dynamic images of the PA (20).

**Planar imaging**

To determine the output function, a chest planar image was acquired after dynamic image acquisition for 5 min (256×256 [1.45 zoom factor and 3.3 mm/pixel]), and the H/M and uptake index (%) on the planar image were calculated. The H/M was calculated using the method reported by Okuda et al. (7). The correlation between the H/M and uptake index was analyzed with respect to the observed clinical features.

**Statistical analysis**

Statistically significant differences according to the patients’ sex were determined using Fisher’s

---

**Table 1.** Classification and clinical diagnoses of 48 patients

| Classification | LBD group (n=21) | non-LBD group (n=27) | p-value* |
|---------------|-----------------|---------------------|----------|
| Sex (M/F)     | 8/13            | 13/14               | 0.836    |
| Age           | 73.5±7.8 (57-89)| 73.5±7.2 (56-84)    | 0.565    |
| Clinical diagnosis |               |                     |          |
| PD (n=16)     | AD (n=5)        |                     |          |
| DLB (n=5)     | VPS (n=7)       |                     |          |
| Other (n=9)   | DPS (n=6)       |                     |          |

LBD, Lewy body disease; DLB, Dementia with Lewy bodies; PD, Parkinson’s disease; AD, Alzheimer’s disease; VPS, Vascular parkinsonism; DPS, Drug-induced parkinsonism. Age data are presented as mean ± standard deviation (range).

*Fisher’s exact test.
exact test for binary variables. Continuous variables are presented as mean ± standard deviation and median. Where indicated, intergroup differences were determined using a two-sided Student’s t-test or the Mann-Whitney U test. The diagnostic values of the H/M and uptake index methods were assessed by calculating the area under the receiver-operating characteristic (ROC) curve. Diagnostic accuracy was evaluated by calculating sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The criterion value of each method was based on the Youden index (J) of the ROC curve. Analyses were performed using MedCalc software (version 12.4). Statistical significance for all analyses was assessed at a probability value of less than 0.05.

Results

Figure 2 shows the linear regression analysis between the H/M and uptake index methods. Both values, obtained by these different techniques, were found to be correlated (r=0.77, P<0.001, n=48).

Figure 3 shows box-and-whiskers plots comparing the LBD and non-LBD patients in the H/M and uptake index. The H/M values of the LBD in ten patients were lower than that of the non-LBD patients (P<0.01). The H/M values of the LBD patients were found to range from 1.29 to 3.34 (mean: 1.92, median: 1.85, interquartile range (IQR): 1.29-2.06, variance: 0.190, 95% CI: 1.72-2.11) and that of the non-LBD patients were within the range of 2.15-3.63 (mean: 2.87, median: 2.80, IQR: 2.60-3.18, variance: 0.176, 95% CI: 2.70-3.03) (Figure 3a). The uptake values of the LBD patients were found to range from 0.66 to 1.22 (mean: 0.86, median: 0.86, IQR: 0.71-0.92, variance: 0.029, 95% CI: 0.78-0.94) and that of the non-LBD patients were within the range of 1.04-
The results and diagnostic accuracy of the uptake index were approximately equal to those of the H/M. The H/M values depend on the system performance of the gamma cameras because of the low count fluctuations of the mediastinum as BG counts (13). Nakajima et al. have tried to standardize the H/M values at multiple facilities in order to reduce this fluctuation (24). Standardization of the H/M method requires the use of a performance conversion coefficient according to system performance. Therefore, a special experiment will be required for calibrating the system in order to obtain the performance conversion coefficient.

Generally, the heart uptake value is obtained by dividing the heart activity (Bq) by the input activity (Bq). When the planar heart and input counts were obtained by one system, the uptake value is calculated without an experimental count-activity conversion calculation (CC), because the CC is offset. Therefore, the uptake value does not depend on the system performance of the gamma cameras. This is an advantage of the uptake index method.

The results of this study were obtained from patients by using a single gamma camera. Further study is necessary to confirm the feasibility of this method.

### Discussion

By analyzing chest RI angiography images, we have established a new uptake index method for $^{123}$I-MIBG heart uptake measurements. The input count was calculated by using the integrated counts of the TAC on the PA ROI, by modifying the simple non-invasive $^{123}$I-IMP quantification based on a microsphere model according to the pharmacokinetics of $^{123}$I-MIBG (19, 20). The heart count was determined using the same method as the H/M.

### Table 2. Diagnostic performance of two variables in the Lewy body disease (LBD) and non-LBD groups

| Method               | AUC  | Sensitivity | Specificity | Cutoff | 95% CI       | PPV | NPV† | Accuracy |
|----------------------|------|-------------|-------------|--------|---------------|-----|------|----------|
| Planar H/M           | 0.95 | 0.93        | 0.91        | <2.30  | 0.87 - 1      | 0.90|      | 0.93     |
| Planar uptake (%)    | 0.98 | 0.96        | 0.91        | <1.12  | 0.95 - 1      | 0.90|      | 0.93     |

AUC, area under the curve; 95% CI, 95 percent confidence interval.

*PPV, positive predictive value; †NPV, negative predictive value.

H/M, heart to mediastinum ratio.
method across multiple facilities. The validity and accuracy would ideally need to be confirmed using planar images in a different patient group.

The input count analysis involves complex techniques. Recently, we developed an automated, simple, and noninvasive $^{123}$I-IMP microsphere input function determination program (auto-SIMS program). This program consisted of two ROI setting programs for the PA and lung regions that used the image phase analysis of a chest RI angiogram (20). An automated uptake index program can be easily developed by modifying the PA ROI setting algorithm of the auto-SIMS program. If this program could be developed, subsequent analysis of the uptake index could be completed with one click in a few seconds, without the need for performing complex analyses. In addition, this automated program will improve the repeatability and reproducibility of this uptake method. When the automated program for the uptake index method is completed, this method could be applied as a useful and stable method in routine clinical studies.

Giorgetti et al. reported a quantification method using $^{123}$I-MIBG SPECT with a CZT camera (18). If the uptake index method using $^{123}$I-MIBG SPECT could be developed by referring to their method, its diagnostic accuracy could be improved, such that its diagnostic accuracy was higher than that of the H/M method.

Conclusion
We developed a simple uptake index method by using $^{123}$I-MIBG planar heart and input counts determined by analyzing chest RI angiography images. The diagnostic accuracy of the uptake index was approximately equal to that of the H/M for discriminating patients with LBD and non-LBD. Further testing is necessary to confirm the feasibility of this method in other facilities.

Acknowledgements
This work was supported by grants (Grant-in-Aid for Scientific Research (C) 26461860) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. No other potential conflict of interest relevant to this article was reported.

References
1. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30(7):1182-91.
2. Merlet P, Valette H, Dubois-Randé JL, Moya D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33(4):471-7.
3. Imamura Y, Fukuyama T. Prognostic value of myocardial MIBG scintigraphy findings in patients with cardiomyopathy—importance of background correction for quantification of MIBG activity. Ann Nucl Med. 2002;16(6):387-93.
4. Oliveira SM, Martins E, Oliveira A, Pinho T, Cavina C, Faria T, et al. Cardiac 123I-MIBG scintigraphy and arrhythmic risk in left ventricular noncompaction. Rev Port Cardiol. 2012;31(3):247-50.
5. Nakajima K, Yoshida M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52(4):378-87.
6. King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. 2011;26(7):1218-24.
7. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18(1):82-9.
8. Treglia G, Cason E, Stefanelli A, Cocciollillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22(1):43-55.
9. Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol. 2003;10(6):623-32.
10. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokol E. Influence of collimator choice and simulated clinical conditions on $^{123}$I-MIBG heart/mediastinum ratio: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32(9):1100-7.
11. Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39(1):113-9.
12. Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21(5):970-8.
13. Sloomka PJ, Mehta PK, Germano G, Berman DS. Quantification of I-123-metaiodobenzylguanidine heart-to-mediastinum ratios: not so simple after all. J Nucl Cardiol. 2014;21(5):979-83.
14. Chen J, Folles RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative I-123 MIBG SPECT in differentiating abnormal and normal MIBG myocardial uptake. J Nucl Cardiol. 2012;19(1):92-9.
15. van der Veen BJ, Al Younis I, de Roos A, Stokkel MP. Assessment of global cardiac I-123 MIBG uptake and
washout using volumetric quantification of SPECT acquisitions. J Nucl Cardiol. 2012;19(4):752-62.
16. Raffel DM, Corbett JR, Schwaiger M, Wieland DM. Mechanism-based strategies for mapping heart sympathetic nerve function. Nucl Med Biol. 1995;22(8):1019-26.
17. Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol. 2001;28(5):541-59.
18. Giorgetti A, Burchielli S, Positano V, Kovalski G, Quaranta A, Genovesi D, et al. Dynamic 3D analysis of myocardial sympathetic innervation: an experimental study using 123I-MIBG and a CZT camera. J Nucl Med. 2015;56(3):464-9.
19. Ofuji A, Mimura H, Yamashita K, Takaki A, Son e T, Ito S. Development of a simple non-invasive microsphere quantification method for cerebral blood flow using I-123-IMP. Ann Nucl Med. 2016;30(3):242-9.
20. Yamashita K, Uchiyama Y, Ofuji A, Mimura H, Okumiya S, Takaki A, et al. Fully automatic input function determination program for simple noninvasive (123) I-IMP microsphere cerebral blood flow quantification method. Phys Med. 2016;32(9):1180-5.
21. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society UPRDS-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.
22. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939-44.
24. Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30(3):188-99.